The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis

Table 3 Summary of the cited meta-analyses and this study

Survival outcomes^a	Total Patients	OS	FFS	DMFS	LRFS
Chen 2015 [17]	206	HR 0.70, 95% CI 0.39–1.26	FE	RR 0.51, 95% CI 0.28–0.95	RR 1.65, 95% CI 0.95–2.86
Song 2015 [18]	798	HR 0.52, 95% CI 0.21–1.29	HR 0.66, 95% CI 0.49–0.90	HR 0.60, 95% CI 0.39–0.98	HR 0.66, 95% CI 0.16–2.65
Ouyang 2019 [19]	1418	FE	FE	FE	FE
Chen 2018 [20]	1193	HR 0.75, 95% CI 0.57–0.99	HR 0.70, 95% CI 0.56–0.86	HR 0.68, 95% CI 0.51–0.90	HR 0.70, 95% CI 0.48–1.01
Tan 2018 [21]	2802	HR 0.77, 95% CI 0.60–0.98	HR 0.69, 95% CI 0.57–0.84	HR 0.63, 95% CI 0.47–0.83	HR 0.66, 95% CI 0.45–0.96
Wang	2311	3-year: HR 0.70, 95% CI 0.55–0.89; 5-year: HR 0.77, 95% CI 0.62–0.94	3-year: HR 0.67, 95% CI 0.55–0.80; 5-year: HR 0.70, 95% CI 0.58–0.83	3-year: HR 0.58, 95% CI 0.45–0.74; 5-year: HR 0.69, 95% CI 0.55–0.87	3-year: HR 0.69, 95% CI 0.50–0.95; 5-year: HR 0.66, 95% CI 0.51–0.86

OS overall survival; FFS failure-free survival; DMFS distant metastasis-free survival; LRFS locoregional relapse-free survival; HR hazard ratio; 95% CI 95% confidence interval; FE fail to extract
^a data of randomized clinical trials

ISSN: 1471-2407